Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

8 things to keep in mind related to the FDA advisory meeting on J&J vaccine

By Brian Buntz | February 25, 2021

Johnson & JohnsonToday, an FDA advisory panel is convening to evaluate the Ad26.COV2.S COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ). 

The vaccine has a favorable safety profile and significant efficacy after a single dose. 

Here are several themes that are likely to be among the topics discussed in the Vaccines and Related Biological Products Advisory Committee meeting. 

1. The J&J vaccine uses an adenovirus vector as opposed to mRNA

In contrast to Moderna and Pfizer’s mRNA vaccines, J&J’s vaccine uses a replication-incompetent recombinant adenovirus type 26 as a vector to express the SARS-CoV-2 spike protein. 

The Ad26 platform is not new, having been administered to nearly 200,000 people in other vaccine candidates. 

AstraZeneca’s COVID-19 vaccine also uses an adenovirus vector, as does the Rusian vaccine Sputnik V.

2. Efficacy is in the ballpark of 67% 

The Moderna and Pfizer two-dose vaccines had efficacy rates in the range of 95% in Phase 3 clinical trials. 

While it is often difficult to compare results of separate clinical studies, the J&J’s vaccine efficacy appears to be a good deal lower — 67% overall. Efficacy was higher in the U.S. (72%) but lower in South Africa (57%), where a highly transmissible variant has achieved broad penetration. 

It’s worth noting that the primary endpoint of the study was the prevention of moderate to severe disease. That is subtly different from the primary endpoint for the Pfizer-BioNTech, Moderna and AstraZeneca studies, which measured their vaccines’ ability to prevent symptomatic COVID-19. 

The J&J vaccine fares better in its ability to prevent severe or critical COVID-19. There, it has overall efficacy of 76.7% and 80.5% in participants between the ages of 18 and 59. 

3. Vaccine efficacy against severe and critical disease increased over time

Vaccine efficacy for the J&J vaccine increased steadily after administration, showing a steady increased 56 days after inoculation. Performance of the vaccine was similar across locations, including areas with a high incidence of circulating variants such as South Africa.

Vaccine efficacy over time

Vaccine efficacy over time for the J&J vaccine.

4. A second dose could boost efficacy

As part of its ENSEMBLE 2 trial, J&J is testing a two-dose regimen of its COVID-19 vaccine. Early data suggests that a second dose boosts the level of neutralizing-antibody titers by a factor of 2.6 to 2.9, “which may well confer more protection,” said vaccine expert Dr. Paul Offit in the VRBPAC meeting. Offit, who is the Vaccine Education Center at Children’s Hospital of Philadelphia, has stressed the importance of the second dose for the mRNA vaccines now available in the U.S.

Early data from non-human primates showed full protection in the lung from a single vaccine dose of the J&J vaccine even four months after administration. The ability of a single dose to provide rapid onset of protection led the company to apply for emergency use authorization for the single-dose regimen.

5. The J&J vaccine could be a powerful tool for ending the pandemic

According to recent research published in Social Science Research Network, a single-dose vaccine with lower efficacy than two-dose vaccines could be a more potent tool in returning society to normalcy. The researchers’ models showed that the single-dose regimen of a vaccine such as J&J’s helps suppress peak infections and cumulative cases more effectively. The models assumed that two-dose vaccines, though ultimately more effective, build up immunity more slowly. 

Complicating matters, however, is recent data from Public Health Matters in the U.K. suggesting that a single dose of the Pfizer/BioNTech vaccine has an efficacy rate of 72% after three weeks — incrementally higher than the Johnson & Johnson vaccine Phase 3 results. The study from Public Health Matters involved 15,121 healthcare workers who had not previously tested positive for COVID-19. 

6. J&J has experience providing similar vaccines to high-risk populations

Johnson & Johnson has used its AdVac platform to vaccinate breastfeeding and pregnant women as well as children within its Ebola program. The company also has experience vaccinating elderly and various populations across continents. Pregnancy could heighten risk of severe illness from COVID-19.

7. The Phase 3 trial was large

Involving 43,325 randomized participants, the J&J Phase 3 clinical trial was about as large as that Pfizer and BioNTech, which had 43,538 participants in November. As of Nov. 20, 38,955 of the Pfizer-BioNtech participants had received two doses of the vaccine. The Moderna trial involved 30,420 participants.

8. Authorization likely happen soon 

Given the favorable clinical trial data and the current vaccine shortage, FDA is likely to allow emergency use authorization of the vaccine in the coming days. Although the efficacy of the single-dose vaccine trails that of the two authorized mRNA vaccines, it is considerably higher than FDA’s efficacy requirement of at least 50%. Furthermore, the vaccine candidate is among the first to have clinical trial data from South Africa and Latin America, two regions with a substantial presence of highly infectious variants. 

Other factors weighing in J&J’s favor are the vaccine’s storage requirements (only requiring refrigeration) and its relative ease of administration as a single-dose vaccine. 

The Ad26.COV2.S was also well tolerated by the majority of clinical trial participants. Most local adverse events were Grade 1 or Grade 2 and were transient. Grade 3 events were infrequent. However, solicited adverse event rates for fever (8.4%), fatigue (16.7%), headache (15.2%) and muscle pain (20.5%) were higher than they were for currently authorized mRNA vaccines. 

A numerical imbalance was observed for thrombotic and thromboembolic events with 14 vaccine recipients having venous thromboembolic events such as deep vein thrombosis or arterial thromboembolic events. A total of 10 placebo recipients had such events .


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, FDA, Johnson & Johnson, VRBPAC
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE